Boston Scientific's preliminary fourth-quarter, full-year sales up

Boston Scientific announced Tuesday preliminary fourth-quarter sales growth of around 9.9 percent to approximately $2.41 billion, above analyst expectations of $2.35 billion. For the full year, sales rose around 7.9 percent to approximately $9.1 billion, meeting prior guidance.

In the quarter, cardiovascular unit sales rose 8.7 percent year-on-year to around $910 million, topping estimates of $896 million, which included an 8.8-percent increase in interventional cardiology revenue to $640 million and an 8.4-percent rise in peripheral interventions sales to $280 million.

Meanwhile, MedSurg revenue increased 14.2 percent over the year-ago period to approximately $930 million, besting predictions of $905 million, with the unit's endoscopy business up 14.8 percent to $440 million, while urology and pelvic health increased 12.7 percent at $310 million. Boston Scientific's rhythm management unit generated sales of around $560 million, representing an increase of 5.4 percent from the prior-year period and broadly meeting estimates, with the unit's cardiac rhythm management revenue up 3.4 percent to $490 million and electrophysiology sales up 20.7 percent year-on-year to $80 million.

Boston Scientific is due to report its fourth-quarter and full-year earnings on February 1.

Did you like this article?